Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Timothy Bailey MD, FACE, CPI

Timothy S. Bailey MD, FACE, CPI

President and CEO, AMCR Institute, Escondido, California; Associate Professor of Medicine, University of California at San Diego, San Diego, California

Dr. Bailey is the CEO and President of the AMCR Institute in Escondido, California and a clinical associate professor of medicine at the University of California at San Diego, where he helps to train endocrinology fellows. He is a past president of the California chapter and former board member of the American Association of Clinical Endocrinologists.

He has served as Principal Investigator on more than 200 phase 1 to 4 clinical trials testing new medications and technology for diabetes including sensors, delivery devices, and the "artificial pancreas". He has a particular interest in human factors testing and real-world trials, with the goal of improving adherence, persistence and the overall effectiveness of therapies for people with diabetes.

Disclosures

Dr. Bailey reports the following disclosures:
  • Research Support: Abbott, Capillary Biomedical , Dexcom, Diasome, Eli Lilly, Kowa, Lexicon, Medtronic, Medtrum, Novo Nordisk, REMD, Sanofi, Senseonics, Viacyte, vTv Therapeutics, Zealand Pharma
  • Consulting Honoraria: Abbott, Lifescan, Novo, Sanofi
  • Speaking Honoraria: Medtronic, Sanofi

Recent Contributions to PracticeUpdate:

  1. Pioglitazone/Exenatide Improves Beta Cell Function and Glycemic Control Compared With Basal/Bolus Insulin in Poorly Controlled T2DM

Most Read This Week

Recently Updated